{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T15:09:15Z","timestamp":1761577755981,"version":"build-2065373602"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"publisher","award":["rs368234815"],"award-info":[{"award-number":["rs368234815"]}],"id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Infection, Genetics and Evolution"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.meegid.2020.104606","type":"journal-article","created":{"date-parts":[[2020,10,27]],"date-time":"2020-10-27T22:29:01Z","timestamp":1603837741000},"page":"104606","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin"],"prefix":"10.1016","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7086-6040","authenticated-orcid":false,"given":"Amany A.","family":"Sakr","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amr E.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed D.E.","family":"Abd El-Maksoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amany","family":"Gamal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hasan","family":"El-garem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Osama M.","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.meegid.2020.104606_bb0005","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/j.1478-3231.2009.02188.x","article-title":"Theneglected hepatitis C virus genotypes 4, 5 and 6: an international consensus report","volume":"30","author":"Antaki","year":"2010","journal-title":"Liver Int."},{"key":"10.1016\/j.meegid.2020.104606_bb0010","doi-asserted-by":"crossref","first-page":"79","DOI":"10.14218\/JCTH.2017.00067","article-title":"Hepatitis C virus and hepatocellular carcinoma: a narrative review","volume":"6","author":"Axley","year":"2018","journal-title":"J Clin. Transl. Hepatol."},{"issue":"3","key":"10.1016\/j.meegid.2020.104606_bb0015","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S2468-1253(16)30181-9","article-title":"Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study","volume":"2","author":"Blach","year":"2016","journal-title":"Lancet Gastroenterol Hepatol."},{"key":"10.1016\/j.meegid.2020.104606_bb0020","first-page":"545","article-title":"Progress toward prevention and control of hepatitis C virus infection\u2013Egypt, 2001\u20132012","volume":"61","author":"Centers for Disease Control and Prevention","year":"2012","journal-title":"MMWR Morb. Mortal. Wkly Rep."},{"issue":"s2","key":"10.1016\/j.meegid.2020.104606_bb0025","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/j.1478-3231.2011.02539.x","article-title":"A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel","volume":"31","author":"Cornberg","year":"2011","journal-title":"Liver Int."},{"issue":"3","key":"10.1016\/j.meegid.2020.104606_bb0030","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","article-title":"Sofosbuvir plus Ribavirin for treating Egyptian patients with hepatitis C genotype 4","volume":"63","author":"Doss","year":"2015","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.meegid.2020.104606_bb0035","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1080\/14787210.2018.1448709","article-title":"HCV in Egypt, prevention, treatment and key barriers to elimination","volume":"16","author":"El Kassas","year":"2018","journal-title":"Expert Rev. Anti-Infect. Ther."},{"year":"2009","series-title":"Egypt Demographic and Health Survey 2008","author":"El-Zanaty","key":"10.1016\/j.meegid.2020.104606_bb0040"},{"key":"10.1016\/j.meegid.2020.104606_bb0045","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nature08309","article-title":"Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance","volume":"461","author":"Ge","year":"2009","journal-title":"Nature."},{"key":"10.1016\/j.meegid.2020.104606_bb0050","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/j.1365-2893.2011.01576.x","article-title":"HCV burden of infection in Egypt: results from a nationwide survey","volume":"19","author":"Guerra","year":"2012","journal-title":"J Viral Hepatol."},{"key":"10.1016\/j.meegid.2020.104606_bb0055","doi-asserted-by":"crossref","first-page":"8935","DOI":"10.3748\/wjg.v21.i29.8935","article-title":"Interferon-lambda polymorphisms and response to pegylated interferon in Iranian hepatitis C patients","volume":"21","author":"Haj-Sheykholeslami","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.meegid.2020.104606_bb0060","doi-asserted-by":"crossref","first-page":"3055","DOI":"10.1038\/emboj.2013.232","article-title":"Interferon lambda 4 signals via the IFNlambdareceptor to regulate antiviral activity against HCV and coronaviruses","volume":"32","author":"Hamming","year":"2013","journal-title":"EMBO J."},{"key":"10.1016\/j.meegid.2020.104606_bb0065","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/apt.13263","article-title":"The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3","volume":"42","author":"Holmes","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.meegid.2020.104606_bb0070","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/nature04226","article-title":"A haplotype map of the human genome","volume":"437","author":"International HapMap Consortium","year":"2005","journal-title":"Nature."},{"key":"10.1016\/j.meegid.2020.104606_bb0075","first-page":"1062","article-title":"Interleukin-28B (rs12979860) gene variation and treatmentoutcome after peginterferon plus Ribavirin therapy in patients with genotype 1 of hepatitis C virus","volume":"19","author":"Kalantari","year":"2014","journal-title":"J Res Med Sci."},{"key":"10.1016\/j.meegid.2020.104606_bb0080","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004681","article-title":"Selection on a variant associated with improved viral clearance drives local, adaptive pseudogenization of interferon lambda 4 (IFNL4)","volume":"10","author":"Key","year":"2014","journal-title":"PLoS Genet."},{"key":"10.1016\/j.meegid.2020.104606_bb0085","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.jhep.2010.11.016","article-title":"Management of hepatitis C virus genotype 4: recommendations of an international expert panel","volume":"54","author":"Khattab","year":"2011","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.meegid.2020.104606_bb0090","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/apt.12601","article-title":"Review article: the efficacy and safety of sofosbuvir, a novel, oral nucleotide NS5B polymerase inhibitor, in the treatment of chronic hepatitis C virus infection","volume":"39","author":"Koff","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.meegid.2020.104606_bb0095","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1038\/s41598-017-17936-4","article-title":"Characterizing hepatitis C virus epidemiology in Egypt: systematic reviews, meta-analyses, and meta-regressions","volume":"8","author":"Kouyoumjian","year":"2018","journal-title":"Sci. Rep."},{"issue":"2","key":"10.1016\/j.meegid.2020.104606_bb0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/j.1469-0691.2010.03432.x","article-title":"Evolving epidemiology of hepatitis C virus","volume":"17","author":"Lavanchy","year":"2011","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.meegid.2020.104606_bb0105","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1084\/jem.20111680","article-title":"Evolutionary genetic dissection of human interferons","volume":"208","author":"Manry","year":"2011","journal-title":"J. Exp. Med."},{"issue":"11","key":"10.1016\/j.meegid.2020.104606_bb0110","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1093\/infdis\/jit827","article-title":"IFNL4-\u0394G genotype is associated with slower viral clearance in hepatitis C, genotype-1 patients treated with Sofosbuvir and ribavirin","volume":"209","author":"Meissner","year":"2014","journal-title":"J. Infect. Dis."},{"year":"2015","series-title":"Egypt Health Issues Survey 2015","author":"Ministry of Health and Population [Egypt], El-Zanaty and Associates [Egypt], and ICF International","key":"10.1016\/j.meegid.2020.104606_bb0115"},{"key":"10.1016\/j.meegid.2020.104606_bb0120","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1002\/hep.26141","article-title":"Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence","volume":"57","author":"Mohd Hanafiah","year":"2013","journal-title":"Hepatology."},{"key":"10.1016\/j.meegid.2020.104606_bb0125","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/ajg.2014.66","article-title":"The rapid evolution of treatment strategies for hepatitis C","volume":"109","author":"Muir","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.meegid.2020.104606_bb0130","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1089\/jir.2013.0136","article-title":"IFN-l4: the paradoxical new member of the interferon lambda family","volume":"34","author":"O\u2019Brien","year":"2014","journal-title":"J. Interf. Cytokine Res."},{"key":"10.1016\/j.meegid.2020.104606_bb0135","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.4049\/jimmunol.1700807","article-title":"IFN-l4 attenuates antiviral responses by enhancing negative regulation of IFN signaling","volume":"199","author":"Obajemu","year":"2017","journal-title":"J. Immunol."},{"issue":"2","key":"10.1016\/j.meegid.2020.104606_bb0140","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1053\/j.gastro.2018.09.052","article-title":"Genetic factors that affect spontaneous clearance of hepatitis C or B virus, response to treatment, and disease progression","volume":"156","author":"O\u2019Brien","year":"2019","journal-title":"Gastroenterology."},{"issue":"1","key":"10.1016\/j.meegid.2020.104606_bb0145","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1002\/hep.28255","article-title":"Interferon lambda 4 genotypes and resistance-associated variants in patients infected with hepatitis C virus genotypes 1 and 3","volume":"63","author":"Peiffer","year":"2016","journal-title":"Hepatology."},{"key":"10.1016\/j.meegid.2020.104606_bb0150","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1038\/ng.2521","article-title":"A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus","volume":"45","author":"Prokunina-Olsson","year":"2013","journal-title":"Nature Genetic."},{"issue":"8","key":"10.1016\/j.meegid.2020.104606_bb0155","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1177\/1060028014534194","article-title":"Sofosbuvir: a nucleotide NS5B inhibitor for the treatment of chronic hepatitis C infection","volume":"48","author":"Rose","year":"2014","journal-title":"Ann Pharmacotherapy."},{"issue":"5","key":"10.1016\/j.meegid.2020.104606_bb0160","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","article-title":"Symonds Sofosbuvir plus Ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry","volume":"62","author":"Ruane","year":"2015","journal-title":"J. Hepatol."},{"issue":"10","key":"10.1016\/j.meegid.2020.104606_bb0165","doi-asserted-by":"crossref","DOI":"10.5812\/hepatmon.22649","article-title":"The impact of IFNL4 rs12979860 polymorphism on spontaneous clearance of hepatitis C; a case-control study","volume":"14","author":"Sharafi","year":"2014","journal-title":"Hepat. Mon."},{"key":"10.1016\/j.meegid.2020.104606_bb0170","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a \u03b2-d-2\u2032-deoxy-2\u2032-\u03b1-fluoro-2\u2032-\u03b2-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.meegid.2020.104606_bb0175","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/ng.447","article-title":"IL28B is associated with response to chronic hepatitis C interferon-alphaand Ribavirin therapy","volume":"41","author":"Suppiah","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.meegid.2020.104606_bb0180","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1038\/ng.449","article-title":"Genome-wide association of IL28B with response to pegylated interferon-alpha and Ribavirin therapy for chronic hepatitis C","volume":"41","author":"Tanaka","year":"2009","journal-title":"Nat. Genet."},{"key":"10.1016\/j.meegid.2020.104606_bb0185","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/apt.12551","article-title":"Review article: the epidemiology and therapy of chronic hepatitis C genotypes 4, 5 and 6","volume":"39","author":"Wantuck","year":"2014","journal-title":"Aliment. Pharmacol. Ther."},{"year":"2016","series-title":"WHO Issuing Updated Guidelines for Treatment of Hepatitis C Infection","author":"World Health Organization","key":"10.1016\/j.meegid.2020.104606_bb0190"}],"container-title":["Infection, Genetics and Evolution"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134820304378?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1567134820304378?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T14:42:53Z","timestamp":1761576173000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1567134820304378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":38,"alternative-id":["S1567134820304378"],"URL":"https:\/\/doi.org\/10.1016\/j.meegid.2020.104606","relation":{},"ISSN":["1567-1348"],"issn-type":[{"type":"print","value":"1567-1348"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Interferon lambda 4 gene polymorphisms as a predicting tool of response to hepatitis C virus genotype 4 patients treated with Sofosbuvir and Ribavirin","name":"articletitle","label":"Article Title"},{"value":"Infection, Genetics and Evolution","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.meegid.2020.104606","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"104606"}}